Table 2.
WHO list of candidate vaccines for COVID-19 in advanced trials [3].
| Sr. No. | Vaccine Platform | Type of Candidate Vaccine | No. of Doses | Adjuvant | Schedule | Route of Administration | Developers | Phase | Clinical Trials (gov.Identifier) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Inactivated virus (IV) | CoronaVac; SARS-CoV-2 vaccine (inactivated) | 2 | Aluminium hydroxide gel (Algel) | Day 0 + 14 | IM | Sinovac Research and Development Co., Ltd. | Phase 4 | NCT04775069 |
| 2 | Inactivated virus (IV) | Inactivated SARS-CoV-2 vaccine (Vero cell) | 2 | Aluminium hydroxide gel (Algel) | Day 0 + 21 | IM | Sinopharm + China National Biotec Group Co + Wuhan Institute of Biological Products | Phase 3 | NCT04612972 |
| 3 | Inactivated virus (IV) | BBIBP-CorV, Inactivated SARS-CoV-2 vaccine (Vero cell) | 2 | Aluminium hydroxide gel (Algel) | Day 0 + 21 | IM | Sinopharm + China National Biotec Group Co + Beijing Institute of Biological Products | Phase 3 | NCT04510207 * |
| 4 | Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) | Inactivated virus vaccine | 2 | Aluminium hydroxide gel (Algel) | Day 0 + 14 | IM | Bharat Biotech International Limited | Phase 3 | NCT04641481; CTRI/2020/11/028976 |
| 5 | SARS-CoV-2 vaccine (vero cells) | Inactivated virus vaccine | 2 | Aluminium hydroxide gel (Algel) | Day 0 + 28 | IM | Institute of Medical Biology + Chinese Academy of Medical Sciences | Phase 3 | NCT04659239 |
| 6 | QazCovid-in® -COVID-19 (Inactivated virus) | Inactivated virus vaccine | 2 | No | Day 0 + 21 | IM | Research Institute for Biological Safety Problems, Rep of Kazakhstan | Phase 3 | NCT04691908 |
| 7 | Viral vector (Non-replicating) (VVnr) | ChAdOx1-S- (AZD1222) (Covishield, Vaxzevria) | 1-2 | No | Day 0 + 28 | IM | AstraZeneca + University of Oxford | Phase 4 | NCT04775069 |
| 8 | Viral vector (Non-replicating) (VVnr) | Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) | 1 | No | Day 0 | IM | CanSino Biological Inc./Beijing Institute of Biotechnology | Phase 4 | NCT04540419 |
| 9 | Viral vector (Non-replicating) (VVnr) | Gam-COVID-Vac Adeno-based (rAd26-S+rAd5-S) | 2 | No | Day 0 + 21 | IM | Gamaleya Research Institute; Health Ministry of the Russian Federation | Phase 3 | NCT04741061 |
| 10 | Viral vector (Non-replicating) (VVnr) | Ad26.COV2.S | 1-2 | aluminum phosphate adjuvant (Adjuphos) | Day 0 or Day 0 +56 | IM | Janssen Pharmaceutical | Phase 3 | NCT04614948 |
| 11 | Protein subunit | SARS-CoV-2 rS/Matrix M1-Adjuvant (Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M) | 2 | Matrix-M™ | Day 0 + 21 | IM | Novavax | Phase 3 | NCT04583995 |
| 12 | Protein subunit | Recombinant SARS-CoV-2 vaccine (CHO Cell) | 2-3 | Aluminium hydroxide gel (Algel) | Day 0 + 28 or Day 0 + 28 + 56 | IM | Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences | Phase 3 | NCT04646590 |
| 13 | Protein subunit | VAT00002: SARS-CoV-2 vaccine formulation 1 with adjuvant 1 (S protein (baculovirus production) | 2 | AS03 | Day 0 + 21 | IM | Sanofi Pasteur + GSK | Phase 3 | PACTR202011523101903 ** |
| 14 | Protein subunit (SOBERANA 02) | FINLAY-FR-2 anti-SARS-CoV-2 Vaccine (RBD chemically conjugated to tetanus toxoid plus adjuvant) | 2 | Aluminium hydroxide gel (Algel) | Day 0 + 28 | IM | Instituto Finlay de Vacunas | Phase 3 | RPCEC00000354 |
| 15 | Protein subunit | EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) | 2 | Aluminium hydroxide gel (Algel) | Day 0 + 21 | IM | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector” | Phase 3 | NCT04780035 |
| 16 | RNA based vaccine | mRNA -1273 | 2 | No | Day 0 + 28 | IM | Moderna + National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 | NCT04760132 |
| 17 | RNA based vaccine | BNT162 (3 LNP-mRNAs), Comirnaty | 2 | No | Day 0 + 21 | IM | Pfizer/BioNTech + Fosun Pharma | Phase 4 | NCT04775069 |
| 18 | RNA based vaccine | CVnCoV Vaccine | 2 | CV8102 | Day 0 + 28 | IM | CureVac AG | Phase 3 | NCT04674189 |
| 19 | DNA based vaccine (ZyCoV-D) | nCov vaccine | 3 | No | Day 0 + 28 + 56 | ID | Zydus Cadila | Phase 3 | CTRI/2020/07/026352 |
IM = intramuscular; ID = intradermal. * This phase 3 trial assesses both the Wuhan (NCT04612972) and Beijing (NCT04510207) vaccine in the same study. ** Pending confirmation on the phase of the study, which is not specified in the registry.